Adriana Cardenas Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 404 1st Ave Sw, Quincy, WA 98848 Phone: 509-787-8992 Fax: 509-787-8995 |
Alyssa Faith Roth-drummond Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 244 J St Se, Quincy, WA 98848 Phone: 509-787-8996 |
Mrs. Tamera Kaye Ybarra, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 21 J St Se, Quincy, WA 98848 Phone: 509-787-8992 |
News Archive
Isis Pharmaceuticals, Inc. today announced that it will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. as a result of OncoGenex' license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a second-generation antisense drug co-discovered by Isis and OncoGenex that has completed a successful Phase 2 program in patients with advanced prostate cancer and advanced non-small cell lung cancer.
Though the drug levodopa can dramatically improve Parkinson's disease symptoms, within five years one-half of the patients using L-DOPA develop an irreversible condition - involuntary repetitive, rapid and jerky movements.
Green tea is touted for its many health benefits as a powerful antioxidant, but experiments in a laboratory mouse model of inflammatory bowel disease suggest that consuming green tea along with dietary iron may actually lessen green tea's benefits.
In the United Kingdom, health experts said that the country could face an exponentially growing death rate from COVID-19 within weeks unless urgent action is taken to control the spread of the virus. At present, the country has the highest official COVID-19 death toll in Europe and the fifth-largest across the globe.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced results from the Phase 2b PEARL-SC clinical study in patients with systemic lupus erythematosus.
› Verified 1 days ago